Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection
Ripamonti, D.; Maggiolo, F.
Current Opinion in Investigational Drugs 9(8): 899-912
2008
ISSN/ISBN: 1472-4472 PMID: 18666038 Document Number: 628276
Tibotec BVBA is developing the diarylpyrimidine rilpivirine, a second-generation non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection. A phase III trial of rilpivirine in HIV-infected, treatment-naive indivuduals is underway and is to be completed by August 2010.
Document emailed within 1 workday
Related Documents
Germanaud, D.; Derache, A.; Traore, M.; Madec, Y.; Toure, S.; Dicko, F.; Coulibaly, H.; Traore, M.; Sylla, M.; Calvez, V.; Marcelin, A.-G. 2010: Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali Journal of Antimicrobial ChemoTherapy 65(1): 118-124Dieterich, D.T. 2003: Long-term complications of nucleoside reverse transcriptase inhibitor therapy Aids Reader 13(4): 176-184; 187
Engchanil, C.; Kosalaraksa, P.; Lulitanond, V.; Lumbiganon, P.; Chantratita, W. 2006: Multi-drug resistant HIV-1 reverse transcriptase genotype in children treated with dual nucleoside reverse transcriptase inhibitors (NRTIs) Journal of the Medical Association of Thailand 89(10): 1713-1720
McMahon, J.B.; Buckheit, R.W.; Gulakowski, R.J.; Currens, M.J.; Vistica, D.T.; Shoemaker, R.H.; Stinson, S.F.; Russell, J.D.; Bader, J.P.; Narayanan, V.L.; Schultz, R.J.; Brouwer, W.G.; Felauer, E.E.; Boyd, M.R. 1996: Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor Journal of Pharmacology and Experimental Therapeutics 276(1): 298-305
Aurpibul, L.; Puthanakit, T.; Taecharoenkul, S.; Sirisanthana, T.; Sirisanthana, V. 2009: Reversal of growth failure in HIV-infected Thai children treated with non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy Aids Patient Care and Stds 23(12): 1067-1071
Weidle, P.J.; Moore, D.; Mermin, J.; Buchacz, K.; Were, W.; Downing, R.; Kigozi, A.; Ndazima, V.; Peters, P.; Brooks, J.T. 2008: Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda Aids Patient Care and Stds 22(10): 787-795
Wainberg, M.A.; Sawyer, J.P.C.; Montaner, J.S.G.; Murphy, R.L.; Kuritzkes, D.R.; Raffi, F. 2005: Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection Antiviral Therapy 10(1): 13-28
Lalezari, J.P.; DeJesus, E.; Northfelt, D.W.; Richmond, G.; Wolfe, P.; Haubrich, R.; Henry, D.; Powderly, W.; Becker, S.; Thompson, M.; Valentine, F.; Wright, D.; Carlson, M.; Riddler, S.; Haas, F.F.; DeMasi, R.; Sista, P.R.; Salgo, M.; Delehanty, J. 2003: A controlled Phase Ii trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults Antiviral Therapy 8(4): 279-287
Mankhatitham, W.; Lueangniyomkul, A.; Manosuthi, W. 2011: Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen Southeast Asian Journal of Tropical Medicine and Public Health 42(3): 651-658
Vemula, S.; Kerr, S.; Pancharoen, C.; Siripong, A.; Kosalaraksa, P.; Engchanil, C.; Chuamchaitrakool, A.; Intasan, J.; Lumbiganond, P.; Phanuphak, P.; Ananworanich, J. 2007: Incidence and risk factors for non-nucleoside reverse transcriptase inhibitors (NNRTI)-related rash in Thai children with HIV infection Journal of the Medical Association of Thailand 90(11): 2437-2441
Duvivier, C.; Ghosn, J.; Assoumou, L.; Soulié, C.; Peytavin, G.; Calvez, V.; Génin, M.èl.A.é; Molina, J.-M.; Bouchaud, O.; Katlama, C.; Costagliola, D.; Beucler, I.; Dion, E.; Raffi, F.; Delfraissy, J.F.; Commoy, M.J.; Massip, P.; Garraffo, R.; Mazetier, L.; Izopet, J.; Chêne, G.; Racheline, A.; Jarousse, B.; Abgrall, S.; Obenga, G.; Phung, B.; Gerbe, J.; Bentata, M.; Honoré, P.; Rami, A.; Delcey, V.; Drener, M.; Parrinello, M.; Miailhes, P.; Lebouche, B.; Kouadjo, K.; Benmakhlouf, N.; Goujard, C.; Miquel, A.; Quetainmont, Y.; Rannou, M.T.; Perronne, C.; de Truchis, P.; Berthé, H.; Jeantils, V.; Tassi, S.; Rozenbaum, W.; Slama, L.; Chakvetaze, C.; Galanaud, P.; Boué, F.; Delavalle, A.M.; Lefebvre, B.; Bollens, D.; Meynard, J.L.; Oua 2008: Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial Journal of Antimicrobial ChemoTherapy 62(4): 797-808
Brzezińska, E.; Glinka, R. 2002: Search for new non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-1 RT) Acta Poloniae Pharmaceutica 59(5): 379-386
2000: Non-nucleoside reverse transcriptase inhibitors. First line therapy MMW Fortschritte der Medizin 142(3 Suppl): 34-35
Tarby, C.M. 2004: Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors Current Topics in Medicinal Chemistry 4(10): 1045-1057
Stankov, M.V.; Lücke, T.; Das, A.M.; Schmidt, R.E.; Behrens, G.M.N. 2007: Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors Antiviral Therapy 12(2): 205-216
Flandre, P.; Descamps, D.; Joly, V.; Meiffrédy, V.; Tamalet, C.; Izopet, J.; Aboulker, J-Pierre.; Brun-Vézinet, Fçoise. 2003: Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received Antiviral Therapy 8(1): 65-72
Mankhatitham, W.; Luaengniyomkul, A.; Manosuthi, W. 2012: Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy Journal of the Medical Association of Thailand 95(2): 163-169
Arenas-Pinto, A.; Bhaskaran, K.; Dunn, D.; Weller, I.V.D. 2008: The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial Antiviral Therapy 13(2): 289-295
Sachdeva, R.K.; Wanchu, A.; Bagga, R.; Malla, N.; Sharma, M. 2010: Effect of non-nucleoside reverse transcriptase inhibitors on cytokine, chemokine, and immunoglobulin profiles in serum and genital secretions of HIV-infected women Journal of Interferon and Cytokine Research: the Official Journal of the International Society for Interferon and Cytokine Research 30(5): 299-310
Ramachandran, G.; Kumar, A.K.Hemanth.; Ponnuraja, C.; Ramesh, K.; Rajesh, L.; Chandrasekharan, C.; Swaminathan, S. 2013: Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients Indian Journal of Medical Research 138(6): 955-961